Embolotherapy Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMMD4082 | Last Updated On: Mar 29 2022 | Available Formats

> Global Embolotherapy Market Expected to reach a high CAGR By 2029: DataM Intelligence

Global Embolotherapy Market is segmented By Product(Microspheres, Embolic coils, Microcatheters, Guidewires, and Others), By Disease(Oncology, Aneurysm, Peripheral vascular diseases, and Others), By End-user(Hospitals and Ambulatory Surgical Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


Market Overview

The global embolotherapy market size was worth US$ YY billion in 2020 and is estimated to reach US$ YY billion by 2028, growing at a CAGR of YY % during the forecast period (2022-2029).

Embolotherapy is a type of endovascular treatment aiming to block abnormal blood vessels to manage hurt, blood vessel malformations, revascularize organs, and scale back tumors. This blockage of blood vessels is called vascular occlusion. For embolization to be successful, three considerations must be followed: embolic agent selection, clinical application, and technical ability. Stainless steel coils, absorbable gelatin pledges and powder, polyvinyl alcohol foam, ethanol, and glues are the main embolic agents used. In the arterial system, both of these agents operate at various levels; for example, coils are similar to surgical ligation and block medium to small arteries, while liquid agents and particles of smaller diameter block at the level of the arteriolar or capillary bed. The type of agent selected, including trauma, cancers, male infertility, impotence, and vascular malformations, should also be determined according to clinical application.

Additionally, the adoption of embolic procedures for managing various diseases is increasing rapidly. Most of the patients diagnosed at the intermediate stage and advanced stage do not respond to curative therapies.

Source: DataM Intelligence Analysis (2020)

Market Dynamics

The global embolotherapy market growth is driven by increasing target patient population of chronic diseases like Liver Cancer, Strokes.

The increasing target patient population of chronic diseases, is expected to drive the growth in the forecast period

The increasing prevalence of several chronic diseases, including cancer, strokes are expected to drive the global Embolotherapy market during the forecasting period. According to the Centre for Disease Control and Prevention (CDC) reports 33,000 people in the US are diagnosed with liver cancer each year. Among these, over 27,000 patients die from the illness and in which 24,000 men and 10,000 women get liver cancer, and about 18,000 men and 9,000 women die from the disease. Additionally, the percentage of people with liver cancer has steadily been increasing in the last decade. Moreover, the survival rate beyond five years remains extremely low, with the percentage hovering between 4 to 26.

On the other hand, Strokes remains the fifth-leading cause of death in the United States, with 7,95,000 cases reported annually and every 40 seconds and every 4 minutes, someone dies of a stroke.

Reimbursement schemes provided by the government for minimally invasive surgeries are also driving the market growth.

In high-income countries, where the government provides 60% healthcare insurance, it has led more people to get their surgeries done. Simultaneously, many low-income countries are also coming up with reimbursement plans to help the public. In multiple Low-Middle Income Countries (LMICs), charitable organizations' equipment has enabled the practice of laparoscopic surgery. In LMICs, minimally invasive procedures for both emergency and elective courses are used. Due to the shortage of funding for equipment and repairs in certain parts of Africa, laparoscopic surgery is much more prevalent in private hospitals.

Stringent regulatory frameworks for product commercialization are likely to hamper market growth.

Microspheres intended for use as artificial emboli and permanent in nature are classed as medical devices artificial embolization devices (AED). They are regulated in the European Union as a Class IIB—in case of bland embolization—under medical device directive MDD 93/42/EEC and in the United States as a Class II vascular and neurovascular embolization device, as their primary mode of action (PMOA) is that of physical occlusion of a vessel. Since PVA particles have been used to indicate vessels' general embolization for over 40 years, they provide a comparative device against which subsequent next-generation products have gained approval or clearance for use based upon substantial equivalence.

With the addition of new features to the embolic devices, the additional burden of proof is necessary to demonstrate the device's continued safety and an appropriate risk–benefit profile for the new product.

COVID-19 Impact Analysis

Due to the covid-19 pandemic outbreak, the global embolotherapy market was down in the production and sale segments. The outbreak led to the shutdown of all manufacturing firms, except for masks, sanitizers and ventilators. Hence, the products were manufactured less compared to previous years during the outbreak.

Segment Analysis

Based on product, the global embolotherapy market is segmented into embolic agents, support devices

Based on products, the global embolotherapy market is segmented into embolic agents and support devices. The embolic agent's section is further sub-segmented into embolic coils, embolic plug systems, microspheres, liquid embolic agents, and detachable balloons. In contrast, microcatheters and guidewires are part of the support devices section.

In 2018, the segment of microspheres under embolic agents had the largest market share. Market growth in this segment is mainly driven by a rise in hepatocellular carcinoma incidence (microspheres are generally used for the treatment of hepatocellular carcinoma), coupled with favorable reimbursement requirements in advanced economies.

The first calibrated microsphere embolic agents that were commercially made available (Biosphere Medical's Embosphere) were tris-acryl gelatin microspheres (TAGM). Clinically, these microspheres have been shown to penetrate more distally than PVA particles, providing more substantial blood loss protection than PVA particles in preoperative meningioma embolization.

Embolic coils are one of the many options for performing embolization. Still, the problem with embolic coils is when coils are deployed to treat bleeding; a forceful saline flush dislodges a thrombus that has been formed around the bleeding site. This is the reason why microspheres are preferred over embolic coils.

Based on disease, the global embolotherapy market is segmented into oncology, aneurysm, peripheral vascular disease.

The embolotherapy market is categorized into oncology, aneurysm, peripheral vascular diseases. The oncology segment, which is the study of tumors, commanded the largest market share in 2018, and over the forecast period between 2019 and 2024, the same segment will rise at the highest CAGR. The reason can be attributed to the growing number of cancer cases worldwide. According to the Centre for Disease Control and Prevention (CDC) reports, 24,000 men and 10,000 women get liver cancer, and about 18,000 men and 9,000 women die from the disease.

Based on end-user, the global embolotherapy market is segmented into hospitals, ambulator surgical centers, clinics

Based on end-user, hospitals are the major shareholders of the market. Reason being hospitals provide with maximum health insurance facilities and are a most trusted resource for treatment and also increasing adoption of minimally invasive surgical procedures for the treatment of urological, neurological, vascular.


Source: DataM Intelligence Analysis (2020)

Geographical Analysis

Asia-Pacific region holds the largest market share in global embolotherapy market

Asia- Pacific holds the largest share in the market. The reason is that the CDC reports that Australia is the leading country with 468 cases of cancer per 100,000 population, followed by New Zealand and Ireland. The reason can be attributed to fast-growing industrialization and the growing consumption of alcohol and drugs. Since the target audience is prominent in Asia- Pacific region, the embolotherapy market demand is most prominent in this region.

North America is reported to be the second-largest shareholder of the market; the decrease in cancer cases is because govt. Of United States is investing a lot towards reducing the cancer cases stats. The U.S. Preventive Services Task Force (USPSTF) routinely carries out comprehensive reviews of the efficacy of clinical prevention services, and the U.S. The Community Preventive Services Task Force assesses the effectiveness of programs affecting populations.

Source: DataM Intelligence Analysis (2020)

Competitive Landscape

The global embolotherapy market is quite competitive with some key competitors like Boston Scientific Corporation, Merit Medical Systems, Terumo Corporation, Medtronic plc, Johnson & Johnson, Stryker Corporation, BTG plc, Penumbra, Inc., Cook Medical, Abbott Laboratories. The growth of these companies is attributed to product launch, acquisition of independent companies and investments in multiple sectors. For example, Terumo acquired the 3M Company's cardiovascular division in July 1999 and founded Terumo Cardiovascular Systems Corp. in the USA. The company made two more acquisitions in 2001: it acquired Sumitomo Bakelite Co., Ltd.'s home oxygen division, and founded Japan's Terumo Medical Care K.K. and Ikiken Co., Ltd. and more.

Boston Scientific Corporation

Company Overview: Boston Scientific Corporation, Leading global manufacturer of medical instruments used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral procedures, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology, and gynaecology, doing business as Boston Scientific.

Product Portfolio: The Company’s portfolio comprised of generic medical devices such as devices for embolization. For example,

Product- Contour PVA Embolization Particles

The Contour PVA Embolization particles are small, irregular flakes of polyvinyl alcohol, used for permanent occlusion within a blood vessel. For decades, in several clinical situations, the Contour PVA Embolization Particles have been shown to be safe and reliable.

Key developments: On 23rd October 2019, Boston Scientific Corporation launched its new embolic protection system for carotid arteries.

Why Purchase the Report?

  • Visualize the composition of the global embolotherapy market segmentation by product type, by disease type, by end-user, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in global embolotherapy market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of global embolotherapy market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global embolotherapy market report would provide an access to an approx. 75 market data table, 66 figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers
Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

Discount Applied

25% discount offer

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!